DEFA14A: Acurx Pharmaceuticals Seeks Shareholder Approval for Reverse Stock Split and Significant Capital Raises

Acurx Pharmaceuticals, Inc. is seeking shareholder approval for a reverse stock split, significant share issuances for capital raising, and an increase in its equity incentive plan ahead of its 2025 Annual Meeting.

Summary

• Acurx Pharmaceuticals, Inc. has filed a Definitive Proxy Statement (DEFA14A) for its 2025 Annual Meeting of Stockholders.
• The meeting is scheduled for July 17, 2025, at 10:00 AM EDT, to be held virtually.
• Shareholders are asked to vote on the re-election of two directors, Mr. Thomas Harrison and Mr. Carl V. Sailer.
• A proposal to ratify CohnReznick LLP as the independent registered public accountants for the fiscal year ending December 31, 2025, is on the agenda.
• The company seeks approval for an amendment to its Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1:10 and not more than 1:30, with the Board of Directors determining the specific ratio, implementation, and timing.
• Shareholder approval is requested for the issuance of shares underlying Series F Warrants and warrants to H.C. Wainwright & Co. LLC, which could amount to 20% or more of common stock outstanding before issuance, pursuant to agreements dated March 6, 2025, and October 9, 2024.
• Approval is also sought for the issuance of shares to Lincoln Park Capital Fund, LLC, potentially 20% or more of common stock outstanding before the May 8, 2025, Purchase Agreement.
• An amendment to the 2021 Equity Incentive Plan is proposed to increase the number of shares available for sale from 177,448 to 2,677,488.

Sentiment

Score: 3

Explanation: The document outlines necessary but generally negative actions for existing shareholders, such as a reverse stock split and significant dilution from capital raises and an expanded equity incentive plan. While these actions are crucial for the company's survival and continued listing, they reflect underlying financial challenges.

Positives

• The company is taking steps to address potential Nasdaq listing compliance issues through a proposed reverse stock split.
• The proposed share issuances are intended to raise capital, which is crucial for a pharmaceutical company's operations and development.
• The increase in the equity incentive plan shares can help attract and retain talent, aligning employee interests with shareholder value.

Negatives

• The proposal for a reverse stock split (1:10 to 1:30) often indicates a low stock price and potential risk of delisting from Nasdaq.
• The proposed issuance of shares underlying Series F Warrants and warrants to H.C. Wainwright & Co. LLC, amounting to 20% or more of outstanding common stock, will result in significant dilution for existing shareholders.
• The proposed issuance of shares to Lincoln Park Capital Fund, LLC, also amounting to 20% or more of outstanding common stock, will further contribute to shareholder dilution.
• The substantial increase in shares available under the 2021 Equity Incentive Plan from 177,448 to 2,677,488 represents significant potential future dilution.

Risks

• Failure to approve the reverse stock split could lead to the company's common stock being delisted from Nasdaq.
• The reverse stock split may not achieve its intended effect of increasing the stock price or maintaining Nasdaq listing, or the stock price may decline again after the split.
• Significant dilution from the issuance of shares for capital raising could negatively impact the per-share value and voting power of existing shareholders.
• The increased shares available for the equity incentive plan could lead to further dilution if fully utilized.

Future Outlook

The document outlines strategic financial and governance actions aimed at ensuring the company's continued operation and Nasdaq listing, including significant capital raising efforts and an expanded equity incentive plan to support future growth and talent retention.

Management Comments

• The Board of Directors recommends a 'For' vote on all proposals presented at the Annual Meeting, including the election of directors, ratification of accountants, reverse stock split, share issuances for capital raising, and the amendment to the equity incentive plan.

Industry Context

Biotechnology and pharmaceutical companies, particularly those in clinical development stages like Acurx Pharmaceuticals, frequently require substantial capital infusions to fund research, development, and operational expenses. Reverse stock splits are a common measure taken by companies with low stock prices to meet exchange listing requirements and attract institutional investors, while equity incentive plans are standard tools for attracting and retaining key personnel in a competitive industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential significant dilution from new share issuances and a reverse stock split, which could impact per-share value and voting power. The reverse split aims to maintain Nasdaq listing, which benefits shareholders by ensuring liquidity.
• Employees: Benefit from the increased shares available under the 2021 Equity Incentive Plan, providing more opportunities for equity-based compensation and incentives.
• Creditors/Investors: The capital raises provide necessary funding, potentially improving the company's financial stability and ability to meet obligations.

Next Steps

• Shareholders are encouraged to vote on the proposals by July 16, 2025.
• The Annual Meeting will be held virtually on July 17, 2025, where the proposals will be voted upon.
• If approved, the Board of Directors will determine the specific ratio, implementation, and timing of the reverse stock split.
• If approved, the company will proceed with the issuance of shares related to the capital raising agreements and the amended equity incentive plan.

Key Dates

Recommendation

Keywords

Acurx Pharmaceuticals, ACXP, SEC filing, DEFA14A, proxy statement, reverse stock split, share issuance, capital raise, equity incentive plan, corporate governance, shareholder meeting, Nasdaq listing, biotechnology, pharmaceuticals